Literature DB >> 7906866

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.

R M Hofstra1, R M Landsvater, I Ceccherini, R P Stulp, T Stelwagen, Y Luo, B Pasini, J W Höppener, H K van Amstel, G Romeo.   

Abstract

Multiple endocrine neoplasia type 2 (MEN 2) comprises three clinically distinct, dominantly inherited cancer syndromes. MEN 2A patients develop medullary thyroid carcinoma (MTC) and phaeochromocytoma. MEN 2B patients show in addition ganglioneuromas of the gastrointestinal tract and skeletal abnormalities. In familial MTC, only the thyroid is affected. Germ-line mutations of the RET proto-oncogene have recently been reported in association with MEN 2A and familial MTC. All mutations occurred within codons specifying cysteine residues in the transition point between the RET protein extracellular and transmembrane domains. We now show that MEN 2B is also associated with mutation of the RET proto-oncogene. A mutation in codon 664, causing the substitution of a threonine for a methionine in the tyrosine kinase domain of the protein, was found in all nine unrelated MEN 2B patients studied. The same mutation was found in six out of 18 sporadic tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906866     DOI: 10.1038/367375a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  220 in total

1.  Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease.

Authors:  G Fitze; M Schreiber; E Kuhlisch; H K Schackert; D Roesner
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

Review 2.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

Review 3.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

4.  The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.

Authors:  J Oriola; I Halperin; F Rivera-Fillat; H Donis-Keller
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

Review 5.  Hirschsprung disease, associated syndromes, and genetics: a review.

Authors:  J Amiel; S Lyonnet
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

6.  A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma.

Authors:  Salud Borrego; Fred A Wright; Raquel M Fernández; Nita Williams; Manuel López-Alonso; Ramana Davuluri; Guillermo Antiñolo; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

Review 7.  Genetic interactions and modifier genes in Hirschsprung's disease.

Authors:  Adam S Wallace; Richard B Anderson
Journal:  World J Gastroenterol       Date:  2011-12-07       Impact factor: 5.742

8.  MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome.

Authors:  Francesca Galuppini; Loris Bertazza; Susi Barollo; Elisabetta Cavedon; Massimo Rugge; Vincenza Guzzardo; Diana Sacchi; Sara Watutantrige-Fernando; Federica Vianello; Caterina Mian; Gianmaria Pennelli
Journal:  Virchows Arch       Date:  2017-08-31       Impact factor: 4.064

9.  How is the Human Genome Project doing, and what have we learned so far?

Authors:  M S Guyer; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families.

Authors:  M Rossel; I Schuffenecker; M Schlumberger; C Bonnardel; E Modigliani; P Gardet; J Navarro; Y Luo; G Romeo; G Lenoir
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.